T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges ...
Location: Germany
Total raised: $20.7M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.12.2025 | Series A | $20.7M | Bayern Kap... |
Mentions in press and media 10
| Date | Title | Description |
| 19.03.2026 | German Biotech Kupando Secures €10M for Advanced Immunotherapy Pipeline | Kupando, a prominent German biotech firm, recently announced substantial new financing. The company secured an additional €10 million in Series A funding. This latest capital infusion elevates its total Series A funding to €23 million. The ... |
| 18.03.2026 | Inspired by animal immunity, Germany’s Kupando raises €10 million for cancer therapy | Schönefeld-based Kupando, a biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity and induces trained immunity for use in oncology and infectious diseases, has secured an additional €10 million in Series A f... |
| 17.03.2026 | German BioTech iDEL Therapeutics lands €9 million to develop cancer therapeutics platform | Dortmund-based iDEL Therapeutics announced the closing of a €9 million Seed financing, to develop a pipeline of cancer therapeutics that are delivered directly into the cytosol of tumor cells. The financing was led by BiomedVC with particip... |
| 23.01.2026 | ErVimmune Unlocks €17M for Groundbreaking Cancer Vaccine Trials | ErVimmune, a Lyon-based biotech, secured €17 million in Series A funding. This pivotal investment propels its innovative off-the-shelf cancer vaccine, ErVac01, into human clinical trials. The company pioneers therapeutic vaccines targeting ... |
| 21.01.2026 | French BioTech company ErVimmune raises €17 million to tackle hard-to-treat cancers | ErVimmune, a BioTech company out of Lyon developing cancer vaccines and cell therapies that target ‘cold tumors’ – cancers that do not respond to current immunotherapies – today announces the first closing of its €17 million ($19.8 million)... |
| 24.12.2025 | T-CURX: $20 Million Series A First Closing Raised To Advance Non-Viral CAR-T Pipeline And In Vivo Platform | T-CURX GmbH said it has completed the first closing of a $20 million (€17.7 million) Series A financing to accelerate the clinical development of its non-viral CAR-T programs in acute myeloid leukemia and solid tumors, while advancing propr... |
| 21.12.2025 | T-CURX Secures $20M Series A to Advance Non-Viral CAR-T Cancer Therapies | German biotech T-CURX closed a $20 million Series A funding round. The Würzburg-based company will accelerate clinical development of its non-viral CAR-T cell therapies. These innovative treatments target acute myeloid leukemia (AML) and so... |
| 17.12.2025 | German startup T-CURX secures €17.7 million to support development of new cancer treatments | Würzburg-based T-CURX today announces the first closing of a €17.7 million Series A to accelerate clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary ... |
| 17.12.2025 | T-Curx Raises $20M in Series A First Closing | T-Curx, a Würzburg, Germany-based biotech company, raised $20M in Series A financing The round was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, as additional investors along with existing and ne... |
| - | T-CURX | “T-CURX develops a new generation of T cells for personalized cancer immunotherapy, built on a proprietary platform that overcome challenges ...” |